Search
forLearn
5 / 801 resultslearn sh-Polypeptide-7
learn PTD-DBM
learn oligopeptide-71
learn ORPL
Research
5 / 102 results
research The effects of GPR40 agonists on hair growth are mediated by ANGPTL4
GPR40 agonists help hair growth through the protein ANGPTL4.
research CD34 + cell–derived fibroblast-macrophage cross-talk drives limb ischemia recovery through the OSM-ANGPTL signaling axis
CD34+ cells help heal damaged limbs by promoting blood vessel growth.
research Cross-Signaling Between Hair Follicle Stem Cells And Dermal Lymphatic Vessels: A Systematic Review
This systematic review explores the interactions between hair follicle stem cells (HFSCs) and dermal lymphatic vessels, highlighting their role in hair growth and tissue regeneration. The review includes 10 studies, mostly in murine models, and reveals that HFSCs and lymphatic vessels engage in dynamic cross-signaling throughout the hair cycle. During the anagen phase, lymphatic vessels dilate and enhance fluid drainage, while HFSCs secrete Angptl7 in the telogen phase to maintain lymphatic function. Lymphatic endothelial cells (LECs) promote HFSC growth by secreting growth signals like IGF-1 and Sostdc1, which activate Wnt signaling. Enhanced lymphangiogenesis prolongs hair growth, whereas LEC depletion leads to hair follicle regression. A human study links aging and alopecia with reduced lymphatic networks. The findings suggest that targeting HFSC-lymphatic signaling could offer new therapeutic avenues for hair loss and wound healing.
research Cross-Signaling Between Hair Follicle Stem Cells And Dermal Lymphatic Vessels: A Systematic Review
This systematic review explores the interactions between hair follicle stem cells (HFSCs) and dermal lymphatic vessels, highlighting their role in hair growth and tissue regeneration. The review includes 10 studies, mostly in murine models, and reveals that HFSCs and lymphatic vessels engage in dynamic cross-signaling throughout the hair cycle. During the anagen phase, lymphatic vessels dilate and enhance fluid drainage, while HFSCs secrete Angptl7 in the telogen phase to maintain lymphatic function. Lymphatic endothelial cells (LECs) promote HFSC growth by secreting growth signals like IGF-1 and Sostdc1, which activate Wnt signaling. Enhanced lymphangiogenesis prolongs hair growth, whereas LEC depletion leads to hair follicle regression. A human study links aging and alopecia with reduced lymphatic networks. The findings suggest that targeting HFSC-lymphatic signaling could offer new therapeutic avenues for hair loss and wound healing.
research In vitro hair growth-promoting effects of araliadiol via the p38/PPAR-γ signaling pathway in human hair follicle stem cells and dermal papilla cells
Araliadiol may promote hair growth like minoxidil without being toxic.
Community Join
5 / 1000+ resultscommunity AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community I’m starting PTD-DBM and valproic acid today - anyone with experience?
The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.